Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 6 (2009), Issue 7 (July)

1. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
   Chin J Integr Med, 15(3): 193-7. [Abstract] [Full-text]
2. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
   Blood, 114(1): 144-7. [Abstract] [Full-text]
3. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
   Blood, 114(1): 148-52. [Abstract] [Full-text]
4. Genomic analysis of acute leukemia.
   Int J Lab Hematol, 31(4): 384-97. [Abstract] [Full-text]
5. Interleukin-10 and interferon-gamma up-regulate the expression of B-cell activating factor in cultured human promyelocytic leukemia cells.
   Exp Mol Pathol, 87(1): 54-8. [Abstract] [Full-text]
6. Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).
   Leuk Res, 33(10): 1405-8. [Abstract] [Full-text]
7. Upregulation of stem cell genes in multidrug resistant K562 leukemia cells.
   Leuk Res, 33(10): 1379-85. [Abstract] [Full-text]
8. The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia.
   Leuk Res, 33(10): 1427-9. [Abstract] [Full-text]
9. Selenite is a potent cytotoxic agent for human primary AML cells.
   Cancer Lett, 282(1): 116-23. [Abstract] [Full-text]
10. c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.
    Leuk Res, 33(10): 1372-8. [Abstract] [Full-text]
11. The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients.
    Leuk Res, 33(10): 1367-71. [Abstract] [Full-text]
12. Molecular variability of FLT3/ITD mutants and their impact on the differentiation program of 32D cells: implications for the biological properties of AML blasts.
    Leuk Res, 33(10): 1409-16. [Abstract] [Full-text]
13. Y-chromosome loss as the sole karyotypic anomaly with 3'RARalpha submicroscopic deletion in a case of M3r subtype of acute promyelocytic leukemia.
    Leuk Res, 33(10): 1433-5. [Abstract] [Full-text]
14. Acute myeloid leukemia with infiltration of thyroid gland complicating Hashimoto's thyroiditis.
    Endocrine, 36(1): 147-50. [Abstract] [Full-text]
15. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
    Blood, 114(2): 257-60. [Abstract] [Full-text]
16. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
    Cancer, 115(14): 3217-21. [Abstract] [Full-text]
17. Interaction of anion exchanger 1 and glycophorin A in human erythroleukaemic K562 cells.
    Biochem J, 421(3): 345-56. [Abstract] [Full-text]
18. Benzene-induced hematopoietic neoplasms including myeloid leukemia in Trp53-deficient C57BL/6 and C3H/He mice.
    Toxicol Sci, 110(2): 293-306. [Abstract] [Full-text]
19. Translocation (1;10)(p34;p15) in infant acute myeloid leukemia with extramedullary infiltration in multiple sites.
    Cancer Genet Cytogenet, 192(2): 86-9. [Abstract] [Full-text]
20. Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia.
    Cancer Genet Cytogenet, 193(1): 9-18. [Abstract] [Full-text]
21. Acute megakaryoblastic leukemia in a child with the MLL-AF4 fusion gene.
    Eur J Haematol, 83(2): 149-53. [Abstract] [Full-text]
22. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Eur J Haematol, 83(2): 99-107. [Abstract] [Full-text]
23. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Eur J Haematol, 83(2): 90-8. [Abstract] [Full-text]
24. Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes.
    Eur J Haematol, 83(2): 108-18. [Abstract] [Full-text]
25. Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia.
    Leukemia, 23(7): 1311-9. [Abstract] [Full-text]
26. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients.
    Leukemia, 23(7): 1303-10. [Abstract] [Full-text]
27. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
    Exp Hematol, 37(8): 979-89. [Abstract] [Full-text]
28. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
    Blood, 114(3): 659-62. [Abstract] [Full-text]
29. Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis.
    Pediatr Blood Cancer, 53(3): 488-90. [Abstract] [Full-text]
30. Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols.
    Pediatr Blood Cancer, 53(3): 325-8. [Abstract] [Full-text]
31. Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
    Int J Cancer, 125(5): 1074-81. [Abstract] [Full-text]
32. Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow.
    Int Ophthalmol, 29(4): 243-5. [Abstract] [Full-text]
33. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.
    Cancer Immunol Immunother, 58(10): 1679-90. [Abstract] [Full-text]
34. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
    Cancer Immunol Immunother, 58(10): 1669-77. [Abstract] [Full-text]
35. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
    Cell, 138(2): 286-99. [Abstract] [Full-text]
36. A new therapeutic target for leukemia comes to the surface.
    Cell, 138(2): 226-8. [Abstract] [Full-text]
37. Relationship correlation of antioxidant and antiproliferative capacity of Cyperus rotundus products towards K562 erythroleukemia cells.
    Chem Biol Interact, 181(1): 85-94. [Abstract] [Full-text]
38. Loss of mismatched HLA in leukemia after stem-cell transplantation.
    N Engl J Med, 361(5): 478-88. [Abstract] [Full-text]
39. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
    J Clin Oncol, 27(22): 3650-8. [Abstract] [Full-text]

© 2004-2010 Acute Myeloid Leukemia Research Today. All Rights Reserved.